A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 11 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 May 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2011-001824-39).